CA2593750A1 - Novel pyrrolodihydroisoquinolines as pde10 inhibitors - Google Patents

Novel pyrrolodihydroisoquinolines as pde10 inhibitors Download PDF

Info

Publication number
CA2593750A1
CA2593750A1 CA002593750A CA2593750A CA2593750A1 CA 2593750 A1 CA2593750 A1 CA 2593750A1 CA 002593750 A CA002593750 A CA 002593750A CA 2593750 A CA2593750 A CA 2593750A CA 2593750 A1 CA2593750 A1 CA 2593750A1
Authority
CA
Canada
Prior art keywords
alkyl
hydrogen
alkoxy
methyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002593750A
Other languages
English (en)
French (fr)
Inventor
Matthias Vennemann
Thomas Bar
Jurgen Braunger
Paola Ciapetti
Jean-Marie Contreras
Camille Georges Wermuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2593750A1 publication Critical patent/CA2593750A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002593750A 2005-01-12 2006-01-11 Novel pyrrolodihydroisoquinolines as pde10 inhibitors Abandoned CA2593750A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05100154.3 2005-01-12
EP05100154 2005-01-12
PCT/EP2006/050167 WO2006089815A1 (en) 2005-01-12 2006-01-11 Novel pyrrolodihydroisoquinolines as pde10 inhibitors

Publications (1)

Publication Number Publication Date
CA2593750A1 true CA2593750A1 (en) 2006-08-31

Family

ID=36097003

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002593750A Abandoned CA2593750A1 (en) 2005-01-12 2006-01-11 Novel pyrrolodihydroisoquinolines as pde10 inhibitors

Country Status (9)

Country Link
US (1) US20080161338A1 (enExample)
EP (1) EP1838707B1 (enExample)
JP (1) JP2008526818A (enExample)
AT (1) ATE430148T1 (enExample)
AU (1) AU2006218054A1 (enExample)
CA (1) CA2593750A1 (enExample)
DE (1) DE602006006544D1 (enExample)
ES (1) ES2326337T3 (enExample)
WO (1) WO2006089815A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05013553A (es) * 2003-06-30 2006-03-09 Altana Pharma Ag Pirrolodihidroisoquinolinas como inhibidores de pde10.
AU2006205797A1 (en) * 2005-01-12 2006-07-20 4Sc Ag Pyrrolodihydroisoquinolines as antiproliferative agents
EP2225248A1 (en) * 2007-11-30 2010-09-08 Wyeth LLC Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
TW200944523A (en) 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
GB201117453D0 (en) * 2011-10-10 2011-11-23 Univ Dundee Improved sperm function/activity
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CN119367368B (zh) * 2024-11-28 2025-12-05 中山大学 氮杂四元环连接的吡唑并吡啶类化合物在制备治疗肺动脉高压的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6930114B2 (en) * 2000-12-13 2005-08-16 Bayer Pharmaceuticals Corporation Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
US20030018047A1 (en) * 2001-04-20 2003-01-23 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) * 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
WO2003014115A1 (en) * 2001-08-06 2003-02-20 Bayer Aktiengesellschaft 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
AU2002366362A1 (en) * 2001-12-18 2003-06-30 Bayer Aktiengesellschaft 2-substituted pyrrolo(2.1-a)isoquinolines against cancer
MXPA05013553A (es) * 2003-06-30 2006-03-09 Altana Pharma Ag Pirrolodihidroisoquinolinas como inhibidores de pde10.

Also Published As

Publication number Publication date
US20080161338A1 (en) 2008-07-03
EP1838707A1 (en) 2007-10-03
DE602006006544D1 (de) 2009-06-10
EP1838707B1 (en) 2009-04-29
ES2326337T3 (es) 2009-10-07
JP2008526818A (ja) 2008-07-24
WO2006089815A1 (en) 2006-08-31
ATE430148T1 (de) 2009-05-15
AU2006218054A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
AU2004253690B2 (en) Pyrrolodihydroisoquinolines as PDE10 inhibitors
EP1641457B1 (en) Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
KR101478517B1 (ko) Ｎ1-피라졸로스피로케톤 아세틸-ｃｏａ 카복실라아제 억제제
JP5972964B2 (ja) 抗腫瘍剤としての三環式および四環式ピラゾロ［３，４−ｂ］ピリジン化合物
EP0937074B1 (en) Benzonaphthyridines as bronchial therapeutics
SG174632A1 (en) Quinolinone derivatives
CA2330738A1 (en) Novel n-oxides of benzonaphthyridines
KR101152439B1 (ko) 신규 히드록시-6-헤테로아릴페난트리딘 및 ｐｄｅ4억제제로서의 이의 용도
EP1838707B1 (en) Novel pyrrolodihydroisoquinolines as pde10 inhibitors
JP2018515489A (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
TW202530189A (zh) ３－苯基丙基胺衍生物
KR20060130697A (ko) 신규한 아미도-치환 히드록시-6-페닐페난트리딘 및 ｐｄｅ4억제제로서의 이의 용도
EP1303506B1 (en) 6-heteroarylphenanthridines
EP1732925A1 (en) Novel n-(alkoxyalkyl)carbamoyl- substituted 6-phenyl-benzonaphthyridine derivatives and their use as pde3/4 inhibitors
KR20060124784A (ko) 신규한 이소아미도 치환된 히드록시-6-페닐페난트리딘 및ｐｄｅ４ 억제제로서의 이의 용도
AU2003264132B2 (en) Novel benzonaphthyridines

Legal Events

Date Code Title Description
FZDE Discontinued